

Ref. No: 1588
Date: 04/03/25
Subject: Treatment of cancers

REQUEST & RESPONSE

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of October 2024 to the end of December 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

PROSTATE CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	0
1.2 Apalutamide (Erleada)	0
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	0
1.4 Darolutamide (Nubeqa)	0
1.5 Enzalutamide (Xtandi)	0
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	0

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	0
2.2 Olaparib (Lynparza) for prostate cancer	0
2.3 Talazoparib (Talzenna) for prostate cancer	0

Q3. How many patients were treated with the following combinations in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT	0
3.2 Olaparib (Lynparza) + Abiraterone	0

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
4.1 Abiraterone	0
4.2 Enzalutamide	0

NIVOLUMAB

Q5. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Nivolumab (Opdivo)	0
5.2 Nivolumab/Relatlimab (Opdualag)	0

Q6. How many patients were treated with Nivolumab (Opdivo) for the following diagnoses in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Diagnosis	Number patients treated
6.1 Malignant melanoma (<i>ICD-10 codes = C43*, C44*, D03*, D485</i>)	0
6.2 Lung Cancer (<i>ICD-10 codes = C34*, C780</i>)	0
6.3 Mesothelioma (<i>ICD-10 codes = C45*, C384, C782</i>)	0
6.4 Renal Cell Carcinoma (<i>ICD-10 codes = C64*, C65*, C790, D410</i>)	0
6.5 Oesophageal or Gastro-Oesophageal Junction (<i>ICD-10 codes = C15*</i>)	0
6.6 Hodgkin Lymphoma (<i>ICD-10 codes = C81*</i>)	0
6.7 Head and Neck Cancer (<i>ICD-10 codes = C00 to C14, C30 to C32, C760, C770</i>)	0
6.8 Urothelial Carcinoma (<i>ICD-10 codes = C67*</i>)	0
6.9 Colorectal Cancer (<i>ICD-10 codes = C18 to C20</i>)	0